Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine

Cardiovascular diseases (CVDs) remain the leading global cause of death and disability, underscoring the need for improved therapies. Key emerging strategies include pharmacological cardioprotection, cell-based therapies and the use of exosomes as therapeutic agents and biomarkers. Aim of this study...

Full description

Saved in:
Bibliographic Details
Main Authors: Hladkykh Fedir V., Matvieienko Mariia M., Liadova Tetiana I, Karafulidi Olha V., Komorovsky Roman R.
Format: Article
Language:English
Published: Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine 2025-01-01
Series:Scripta Medica
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503521H.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849409085288480768
author Hladkykh Fedir V.
Matvieienko Mariia M.
Liadova Tetiana I
Karafulidi Olha V.
Komorovsky Roman R.
author_facet Hladkykh Fedir V.
Matvieienko Mariia M.
Liadova Tetiana I
Karafulidi Olha V.
Komorovsky Roman R.
author_sort Hladkykh Fedir V.
collection DOAJ
description Cardiovascular diseases (CVDs) remain the leading global cause of death and disability, underscoring the need for improved therapies. Key emerging strategies include pharmacological cardioprotection, cell-based therapies and the use of exosomes as therapeutic agents and biomarkers. Aim of this study was to characterise contemporary approaches to cardioprotection in CVDs, including pharmacological agents, cell-based therapies and exosome-based strategies, based on an analysis of evidence-based data. A systematic literature search was performed using databases including PubMed, Clinical Key (Elsevier), Cochrane Library, eBook Business Collection and Google Scholar. Keywords included cardioprotection, exosomes, cell-based therapies and pharmacological approaches. Article selection followed evidence-based medicine principles and the PRISMA guidelines. Current cardioprotective strategies include both traditional pharmacological agents, such as b-blockers, calcium channel blockers, ACE inhibitors, statins and nitrates, as well as innovative approaches like cell-based therapies and the use of exosomes. The advantages and limitations of cell therapy were analysed, including challenges related to low cell survival, failure of differentiation and the risk of arrhythmias. The role of exosomes and microvesicles as promising markers of cardiovascular injury and potential therapeutic agents was also explored. Combining pharmacological, cell-based and exosome-based strategies offers new prospects for cardioprotection in CVDs. Further research is required to optimise the clinical use of cell therapies and to confirm the efficacy of exosome-based interventions.
format Article
id doaj-art-0aef2be5b63f4f0e9d7d63fd9127e835
institution Kabale University
issn 2490-3329
2303-7954
language English
publishDate 2025-01-01
publisher Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
record_format Article
series Scripta Medica
spelling doaj-art-0aef2be5b63f4f0e9d7d63fd9127e8352025-08-20T03:35:37ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542025-01-0156352153510.5937/scriptamed56-587192490-33292503521HAdvances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicineHladkykh Fedir V.0https://orcid.org/0000-0001-7924-4048Matvieienko Mariia M.1https://orcid.org/0000-0002-0388-138XLiadova Tetiana I2https://orcid.org/0000-0002-5892-2599Karafulidi Olha V.3https://orcid.org/0009-0008-4669-6708Komorovsky Roman R.4https://orcid.org/0000-0002-0288-4132Grigoriev Institute for Medical Radiology and Oncology, Radiation Pathology and Palliative Medicine Group, Radiology Department, Kharkiv, UkraineV. N. Karazin Kharkiv National University, Department of General Surgery, Anaesthesiology and Palliative Medicine, Kharkiv, UkraineV. N. Karazin Kharkiv National University, Department of Infectious Diseases and Clinical Immunology, Kharkiv, UkraineO.I. Meshchaninov Kharkiv City Emergency Clinical Hospital, Anaesthesiology and Intensive Care Unit, Kharkiv, UkraineIvan Horbachevsky Ternopil National Medical University, Department of Internal Medicine II, Ternopil, UkraineCardiovascular diseases (CVDs) remain the leading global cause of death and disability, underscoring the need for improved therapies. Key emerging strategies include pharmacological cardioprotection, cell-based therapies and the use of exosomes as therapeutic agents and biomarkers. Aim of this study was to characterise contemporary approaches to cardioprotection in CVDs, including pharmacological agents, cell-based therapies and exosome-based strategies, based on an analysis of evidence-based data. A systematic literature search was performed using databases including PubMed, Clinical Key (Elsevier), Cochrane Library, eBook Business Collection and Google Scholar. Keywords included cardioprotection, exosomes, cell-based therapies and pharmacological approaches. Article selection followed evidence-based medicine principles and the PRISMA guidelines. Current cardioprotective strategies include both traditional pharmacological agents, such as b-blockers, calcium channel blockers, ACE inhibitors, statins and nitrates, as well as innovative approaches like cell-based therapies and the use of exosomes. The advantages and limitations of cell therapy were analysed, including challenges related to low cell survival, failure of differentiation and the risk of arrhythmias. The role of exosomes and microvesicles as promising markers of cardiovascular injury and potential therapeutic agents was also explored. Combining pharmacological, cell-based and exosome-based strategies offers new prospects for cardioprotection in CVDs. Further research is required to optimise the clinical use of cell therapies and to confirm the efficacy of exosome-based interventions.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503521H.pdfcardiovascular diseasesprevention and control, cardiacexosomescell and tissue-based therapytherapeuticsischaemiaischaemic injuryregenerative medicineadrenergic beta-antagonistscalcium channel blockersmicrovesicles
spellingShingle Hladkykh Fedir V.
Matvieienko Mariia M.
Liadova Tetiana I
Karafulidi Olha V.
Komorovsky Roman R.
Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
Scripta Medica
cardiovascular diseases
prevention and control, cardiac
exosomes
cell and tissue-based therapy
therapeutics
ischaemia
ischaemic injury
regenerative medicine
adrenergic beta-antagonists
calcium channel blockers
microvesicles
title Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
title_full Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
title_fullStr Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
title_full_unstemmed Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
title_short Advances in cardioprotective strategies: Bridging traditional pharmacotherapy and regenerative medicine
title_sort advances in cardioprotective strategies bridging traditional pharmacotherapy and regenerative medicine
topic cardiovascular diseases
prevention and control, cardiac
exosomes
cell and tissue-based therapy
therapeutics
ischaemia
ischaemic injury
regenerative medicine
adrenergic beta-antagonists
calcium channel blockers
microvesicles
url https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503521H.pdf
work_keys_str_mv AT hladkykhfedirv advancesincardioprotectivestrategiesbridgingtraditionalpharmacotherapyandregenerativemedicine
AT matvieienkomariiam advancesincardioprotectivestrategiesbridgingtraditionalpharmacotherapyandregenerativemedicine
AT liadovatetianai advancesincardioprotectivestrategiesbridgingtraditionalpharmacotherapyandregenerativemedicine
AT karafulidiolhav advancesincardioprotectivestrategiesbridgingtraditionalpharmacotherapyandregenerativemedicine
AT komorovskyromanr advancesincardioprotectivestrategiesbridgingtraditionalpharmacotherapyandregenerativemedicine